Indications for PLEGRIDY:
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Give by SC inj in abdomen, back of the upper arm, or thigh; rotate inj sites. Initially 63mcg on Day 1, increase to 94mcg on Day 15, then 125mcg on Day 29 and every 14 days thereafter. May give analgesics and/or antipyretics for flu-like symptoms.
Depression. Suicidal ideation. Consider discontinuing if depression or other severe psychiatric symptoms occur. Seizure disorder. Discontinue if serious allergic reactions occur. Significant cardiac disease; monitor for worsening condition at initiation and during treatment. Risk of thrombotic microangiopathy; discontinue if occurs. Monitor for hepatic injury, infections, bleeding, anemia. Myelosuppression. Obtain CBCs with differential and platelets during treatment. Consider discontinuing if new autoimmune disorder develops. Severe renal impairment: monitor. Pregnancy. Nursing mothers.
Inj site reactions (erythema, pain, pruritus), influenza-like illness, pyrexia, headache, myalgia, chills, asthenia, arthralgia; hepatic injury, seizures, anaphylaxis, CHF, hematologic or autoimmune disorders, inj site necrosis (suspend therapy if multiple lesions occur).
To enroll women exposed to Plegridy during pregnancy call (866) 810-1462 or visit https://www.plegridypregnancyregistry.com/.
Renal. Half-life: ~78 hours.
Generic Drug Availability:
Single-dose prefilled pen (0.5mL)—2; Single-dose prefilled syringe (0.5mL)—2; Starter Pack (pens and syringes)—2 (63mcg + 94mcg)